|Ms. Lynn Sadowski Mason M.S.||Exec. VP of Clinical Operations||362.5k||N/A||1979|
|Mr. Ronald Guido M.S.||Chief Devel. Officer & Sec.||382.5k||N/A||1957|
|Dr. Howard J. Federoff M.D., Ph.D.||CEO, Pres & Director||N/A||N/A||1953|
|Ms. Sandra M. Gurrola||VP of Fin.||N/A||N/A||1967|
|Dr. Monil Shah M.B.A., Pharm.D.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Kevin A. D'Amour Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Jay Sial||Chief Admin. Officer||N/A||N/A||N/A|
|Dr. Roger Sidhu M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Susan McClatchey||VP & Head of Quality||N/A||N/A||N/A|
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Brooklyn ImmunoTherapeutics, Inc.’s ISS governance QualityScore as of 1 February 2022 is 7. The pillar scores are Audit: 10; Board: 3; Shareholder rights: 7; Compensation: 7.